Clinical trial Recruiting at 1 site Interventional Ages 20 to 80

Hybrid mirror-primed rehabilitation for unilateral stroke

Official title: Hybrid Stroke Rehabilitation With Mirror Priming

Run by I-Shou University · NCT07324278 · Data updated 2026-11-12

This trial will test whether adding enhanced mirror priming to conventional therapy helps adults who had a first-time one-sided stroke at least three months ago improve upper-arm movement.

Quick facts

Study typeInterventional
Ages20 Years to 80 Years
SexAll
Enrollment81 (estimated)
SponsorI-Shou University
Academic / other
Locations1 site (Kaohsiung City, Yanchao District)
StatusRecruiting
StartedFebruary 2, 2026
Main results expectedSeptember 30, 2030
Study endsDecember 31, 2030
Registry record updatedAugust 25, 2026
Trial IDNCT07324278 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 20–80 with a first-ever unilateral stroke at least three months earlier, a baseline FMA-UE score greater than 10, no severe spasticity in the affected arm, and the ability to follow instructions and provide consent.

Probably not a fit

Patients with severe spasticity, very low baseline motor scores, unstable medical conditions, or those within three months of a stroke are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares an enhanced mirror priming approach combined with conventional therapy to conventional therapy alone to optimize and personalize upper-limb rehabilitation after unilateral stroke. Participants are adults aged 20–80 with a first-ever unilateral stroke at least three months prior and a baseline Fugl-Meyer Assessment Upper Extremity score above 10, with no severe spasticity and the ability to follow instructions. The program delivers supervised in-person sessions at E-Da Hospital where mirror-priming procedures are applied alongside standard rehabilitation exercises to promote motor relearning. Primary outcomes will focus on changes in upper-extremity motor function and the tolerability of the enhanced priming protocol.

Why it matters

Potential benefit: If successful, the approach could improve upper-arm motor recovery and enable more personalized rehabilitation plans for people with chronic unilateral stroke.

How similar studies have gone: Traditional mirror therapy has shown modest motor benefits in prior studies, while enhanced or hybrid mirror-priming approaches are relatively novel with limited published evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. A first-ever unilateral stroke ≥3 months
2. Age between 20 and 80 years
3. Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score ≥ 10
4. No severe spasticity in any joints of the affected arm
5. Ability to follow the instructions
6. No participation in other studies during the study period
7. Willingness to provide informed written consent.

Exclusion Criteria:

1. Serious medical problems or poor physical conditions that might be detrimental to study participation.
2. Received or planned botulinum toxin injections within 3 months prior to or during the trial

Where it's running

  • E-Da Hospital
    Kaohsiung City, Yanchao District, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Remote ischemic conditioning after aneurysm clipping for ruptured brain aneurysms

    This test tries brief cycles of limb cuff inflation (remote ischemic conditioning) to see if it is safe and helps recovery in adults after surgical clipping of a ruptured brain aneurysm (aneurysmal subarachnoid hemorrhage).

    Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT06819657

  • Rural Telemedicine-Enabled Care to Prevent Stroke in Older Adults in China

    A telemedicine-supported care model led by rural doctors will be tested to see if it can reduce stroke and heart problems in adults 65+ living in rural China.

    Recruiting at 2 sites Jiangsu Province (Suqian) Hospital · Suqian, Jiangsu and 1 other locations · NCT07628283

  • Best Care for Acute Stroke in General Wards

    A nurse-led program called BEST CARE ICTUS_HC is tested in hospitals without Stroke Units to see if it reduces stroke complications and helps recovery after an acute ischemic or hemorrhagic stroke.

    Recruiting University of Malaga · Antequera, Málaga and 3 other locations · NCT07627399

  • Intra-arterial clot-dissolving treatment for medium-vessel ischemic stroke

    The team will test whether giving tenecteplase directly into the artery helps adults with acute ischemic stroke caused by medium-vessel blockage or severe narrowing.

    Recruiting at 6 sites The Second Hospital of Anhui Medical University · Fuyang, Anhui and 5 other locations · NCT07185022

  • Dimephosphon® for recovery after acute ischemic stroke.

    This trial will test whether Dimephosphon® given 24–72 hours after stroke onset helps adults with moderate acute ischemic stroke recover better than a placebo.

    Recruiting at 5 sites Phase 3 Tatchempharmpreparaty, JSC · Vsevolozhsk, Leningradskaya Oblast' and 5 other locations · NCT07167550

  • Home-based cognitive strategy training to support daily living after chronic stroke

    This pilot tests whether a home-delivered cognitive strategy program (PRPP-I) can help adults with chronic stroke become more independent in daily activities and improve quality of life.

    Recruiting University Hospital, Toulouse · Toulouse · NCT07084025

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.